|
|
| (37 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| {{Gemfibrozil}}
| | |valign=top| |
| {{CMG}}; {{AE}} {{SS}} | | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| '''''For patient information about Gemfibrozil, click [[Gemfibrozil (patient information)|here]].'''''
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| {{SB}} LOPID<sup>®</sup>,generic
| | |- |
| | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| ==Overview==
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| '''Gemfibrozil''' is the [[International Nonproprietary Name|generic name]] for an oral drug used to lower [[lipid]] levels. It belongs to a group of drugs known as [[fibrates]]. It is most commonly sold as the brand name, '''Lopid'''.
| | |} |
| | |
| ==Category==
| |
| | |
| Cardiovascular Drug,Phenol ethers,Fibrates，Lipid modifying agents
| |
| ==FDA Package Insert== | |
| | |
| ''' [[Gemfibrozil indications and usage|Indications and Usage]]'''
| |
| '''| [[Gemfibrozil dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Gemfibrozil contraindications|Contraindications]]'''
| |
| '''| [[Gemfibrozil warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Gemfibrozil adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Gemfibrozil drug interactions|Drug Interactions]]'''
| |
| '''| [[Gemfibrozil use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Gemfibrozil overdosage|Overdosage]]'''
| |
| '''| [[Gemfibrozil description|Description]]'''
| |
| '''| [[Gemfibrozil clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Gemfibrozil nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Gemfibrozil how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Gemfibrozil labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| The mechanism of action of gemfibrozil has not been definitely established. In man, LOPID has been shown to inhibit peripheral lipolysis and to decrease the hepatic extraction of free fatty acids, thus reducing hepatic [[triglyceride]] production. LOPID inhibits synthesis and increases clearance of VLDL carrier [[apolipoprotein B]], leading to a decrease in [[VLDL]] production.
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Lipid modifying agents}}
| |
| | |
| [[Category:Fibrates]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drug]]
| |
| [[Category:Drug]]
| |